findmyKOL
Clinical trialNCT06732388RecruitingPhase 2Interventional

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

SponsorNational Cancer Institute (NCI)Enrollment76Barrett EsophagusClinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Esophageal Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well itraconazole works in combination with the usual standard of care endoscopy with ablation for the prevention of esophageal cancer in patients who have high-risk Barrett's esophagus (BE). BE is a condition in which the lining of the esophagus changes and becomes more like the tissue that lines the intestine. People with Barrett's esophagus have a higher risk of developing esophageal cancer. Itraconazole is a drug used to prevent or treat fungal infections. Ablation refers to the removal of abnormal tissue using heat. Endoscopy is a procedure for looking at the esophagus using a long, flexible tube called an endoscope, which has a video camera at the end. Radiofrequency ablation is a type of heat therapy that uses radiofrequency energy (similar to microwave heat) to destroy the abnormal tissue in the esophagus. Giving itraconazole in combination with standard of care endoscopy with ablation may improve the effects of ablation and prevent esophageal cancer in patients with high-risk Barrett's esophagus.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Kansas Cancer Center

    Kansas City, Kansas, United States

    Ajay Bansal
    Not, yet, recruiting
  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States

    David Wang
    Recruiting
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Paul E. Wise
    Recruiting
  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

    Nicholas J. Shaheen
    Recruiting
  • Case Western Reserve University

    Cleveland, Ohio, United States

    Not, yet, recruiting
  • Baylor University Medical Center

    Dallas, Texas, United States

    Vani Konda
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Itraconazole →Placebo Administration
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Jun 2026
Primary completion
1 Aug 2030
Completion
1 Dec 2030
Last update posted
29 Jul 2026
Registered enrollment
76
Registry id
NCT06732388

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.